<DOC>
	<DOCNO>NCT01652911</DOCNO>
	<brief_summary>This open-label , single arm , non-randomized safety efficacy study , participant Type-1 diabetes receive Sernova Cell Pouch™ implant subcutaneous site , two approximately twelve week prior transplantation islet Cell Pouch™ . The primary objective study assess safety Sernova Cell Pouch™ adult participant Type-1 diabetes receive islet transplantation first time . Secondary objective follow : 1 . To determine proportion subject implant Cell Pouch™ transplant islet Cell Pouch™ achieve maintain insulin independence islet transplantation . 2 . To obtain preliminary data efficacy Cell Pouch™ maintain adequate immunological protection allo- autoimmunity islet transplant recipient . 3 . To determine retrospective analysis comparative metabolic function engraftment efficiency use patient undergo standard intraportal islet transplantation current alemtuzumab standard care protocol .</brief_summary>
	<brief_title>A Phase I/II Study Safety Efficacy Sernova 's Cell PouchTM Therapeutic Islet Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>To eligible participant must T1DM 5 year , complicate least 1 follow situation persist despite intensive insulin management effort : 1 . Reduced awareness hypoglycemia , define absence adequate autonomic symptom plasma glucose level &lt; 3.0 mmol/L , indicate , 2 episode severe hypoglycemia require third party assistance within 12 month , Clarke score ≥4 , HYPO score ≥1,000 , lability index ( LI ) ≥400 combine Hypo/LI &gt; 400/300 2 . Metabolic instability , characterize erratic blood glucose level interfere daily activity 2 hospital visit diabetic ketoacidosis last 12 month . Participants must capable understand purpose risk study must sign statement informed consent . 1 . Severe coexist cardiac disease , characterize one condition : ( ) recent myocardial infarction ( within past 6 month ) ; ( b ) leave ventricular ejection fraction &lt; 30 % ; ( c ) evidence ischemia functional cardiac exam . 2 . Active alcohol substance abuse , include cigarette smoking ( must abstinent 6 month prior transplant ) . 3 . Psychiatric disorder make subject suitable candidate transplantation , ( e.g. , schizophrenia , bipolar disorder , major depression unstable uncontrolled current medication ) . 4 . History nonadherence prescribe regimen . 5 . Active infection include Hepatitis C , Hepatitis B , HIV , TB ( subject positive PPD perform within one year enrollment , history adequate chemoprophylaxis ) . 6 . Any history current malignancy except squamous basal skin cancer . 7 . BMI &gt; 35 kg/m2 screen visit . 8 . Age le 18 great 68 year . 9 . Measured glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73 m2 . 10 . Presence history macroalbuminuria ( &gt; 300 mg/g creatinine ) . 11 . Clinical suspicion nephritic ( hematuria , active urinary sediment ) rapidly progress renal impairment ( e.g . Increase serum creatinine 25 % within last 36 month ) . 12 . Baseline Hb &lt; 105g/L woman , &lt; 120 g/L men . 13 . Baseline screen liver function test outside normal range , exception uncomplicated Gilbert 's Syndrome . An initial LFT panel value &gt; 1.5 time upper limit normal ( ULN ) exclude patient without retest ; test value ULN 1.5 time ULN make , value remain elevated normal limit , patient exclude . 14 . Untreated proliferative retinopathy . 15 . Positive pregnancy test , intent future pregnancy male subject ' intent procreate , failure follow effective contraceptive measure , presently breast feed . 16 . Previous transplant evidence significant sensitization PRA ( discretion investigator ) . 17 . Insulin requirement &gt; 1.0 U/kg/day 18 . HbA1C &gt; 12 % . 19 . Uncontrolled hyperlipidemia [ fast LDL cholesterol &gt; 3.4 mmol/L , treat untreated ; and/or fast triglyceride &gt; 2.3 mmol/L ] . 20 . Under treatment medical condition require chronic use steroid . 21 . Use coumadin anticoagulant therapy ( except aspirin ) subject PT INR &gt; 1.5 . 22 . Untreated Celiac disease . 23 . Patients Graves disease exclude unless previously adequately treated radioiodine ablative therapy . 24 . Any medical condition , opinion clinical investigator , interfere safe participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Islet Transplantation</keyword>
	<keyword>Cell Pouch</keyword>
</DOC>